STOCK TITAN

Verrica Pharmaceuticals Inc - VRCA STOCK NEWS

Welcome to our dedicated news page for Verrica Pharmaceuticals (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Verrica Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Verrica Pharmaceuticals's position in the market.

Rhea-AI Summary
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that its partner, Torii Pharmaceutical Co., Ltd., reported positive top-line results from its Phase 3 trial of TO-208 (VP-102, marketed as YCANTH™) for the treatment of Molluscum Contagiosum in Japan. The trial showed statistically significant efficacy versus placebo, with well-tolerated results. Verrica and Torii signed an exclusive licensing agreement for the development and commercialization of VP-102 in Japan, taking a step closer to addressing the underserved patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
61.97%
Tags
-
Rhea-AI Summary
VRCA: Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London on November 15, 2023. Ted White, Verrica President & CEO, to discuss dermatology therapeutics development. Live webcast available on Verrica website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
none
-
Rhea-AI Summary
Verrica Pharmaceuticals Inc. (VRCA) announced strong interest in prescribing YCANTH™ for molluscum treatment, covering over 112 million lives on commercial insurance and managed Medicaid plans. Financial results for Q3 2023 included $2.8 million net product revenue. The company also highlighted progress on the development pipeline, including VP-315 for basal cell carcinoma and VP-102 for common warts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
Rhea-AI Summary
Verrica Pharmaceuticals will host a conference call and webcast on November 9, 2023, to discuss its financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Verrica Pharmaceuticals will host a virtual KOL event discussing the approval of YCANTH™ topical solution for molluscum contagiosum on Oct 11. YCANTH™ is the only FDA-approved product for treating molluscum in adults and pediatric patients. Molluscum affects approximately 6 million people in the US, primarily children. Without treatment, it can last up to 5 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
conferences
-
Rhea-AI Summary
Verrica Pharmaceuticals CEO to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
Rhea-AI Summary
Verrica Pharmaceuticals announces first commercial sale of YCANTH™, an FDA-approved treatment for molluscum, to exclusive distributor FFF Enterprises.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary
Verrica supports FDA's action against unapproved molluscum contagiosum products
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary
Verrica Pharmaceuticals presented lesion clearance data from Part 1 of a Phase 2 study of VP-315 for the treatment of basal cell carcinoma (BCC). The study showed consistent clinical and histological clearance of treated BCC lesions with the 8 mg dose of VP-315, with 67% of subjects showing complete tumor clearance. The company plans to expand Part 2 of the trial based on these positive results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
Verrica Pharmaceuticals Inc

Nasdaq:VRCA

VRCA Rankings

VRCA Stock Data

291.42M
15.07M
39.7%
42.59%
9.87%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
West Chester

About VRCA

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.